LADA

 🔴 CME INDIA | CLINICAL PEARLS

LADA in Routine Practice: From Misdiagnosis to Precision Care

Authors: Hitesh Saraogi — Dhanwantari Hospital, Ghaziabad, India; Wahid Khan — Apollo Superspeciality Hospital, Muscat, Oman.

Top 12 Clinical Pearls

1. LADA is the diabetes we frequently call “Type 2” too early.

It is an autoimmune diabetes with gradual β-cell destruction, often initially resembling T2DM because insulin may not be required at diagnosis. 

2. The burden is clinically important.

The review estimates that approximately 4–14% of people initially diagnosed with T2DM may actually have an autoimmune phenotype consistent with LADA. 

3. Think of diabetes as a spectrum rather than rigid boxes.

LADA occupies the middle ground between classical T1DM and T2DM: autoimmunity like T1DM, but slower β-cell loss and often some insulin resistance like T2DM. The authors’ schematic nicely illustrates this continuum. 

4. When should the physician suspect LADA?

Reconsider the diagnosis of T2DM when an adult has relatively young onset, lower/normal BMI, unexpected weight loss, autoimmune background, rapidly worsening HbA1c, or an unexpectedly early requirement for insulin despite apparently appropriate oral therapy.

5. GAD antibody is the key first antibody.

GADA is the most commonly detected islet autoantibody in LADA. Additional antibodies can improve characterization when clinical suspicion remains high. 

6. C-peptide tells you how much β-cell reserve remains.

Autoantibodies establish autoimmunity; C-peptide provides complementary information about residual endogenous insulin secretion and can help guide therapeutic intensity. The article specifically highlights both GAD antibodies and C-peptide as central to precision classification. 

7. A single phenotype does not describe all LADA.

β-cell decline is heterogeneous. Some patients rapidly become insulin dependent, while others retain useful insulin secretion for years. This explains why LADA is easily missed in routine practice. 

8. Poor response to conventional T2DM therapy is a diagnostic clue—not merely “noncompliance.”

When glycemia progressively deteriorates despite reasonable lifestyle measures and glucose-lowering therapy, revisit the type of diabetes, not just the dose of drugs.

9. Avoid therapeutic inertia while β-cells disappear.

Conventional T2DM algorithms may not adequately address the progressive autoimmune β-cell loss of LADA. Earlier recognition allows treatment to be individualized rather than repeatedly escalating oral drugs. 

10. Insulin should not be viewed as “failure.”

Progressive insulin deficiency is intrinsic to the biology of LADA. The timing of insulin should therefore be driven by glycemia, symptoms and β-cell reserve rather than waiting for severe metabolic deterioration.

11. Be cautious with drugs in patients becoming insulin deficient.

Particularly when C-peptide is low or declining, therapies that can expose an insulin-deficient patient to ketosis deserve extra caution. The clinical priority is to recognize impending insulin dependence before severe hyperglycemia or ketoacidosis occurs.

12. Precision diabetes care begins with correct classification. 🧬

Adult-onset diabetes should not automatically equal T2DM. Combining clinical phenotype + islet autoantibodies + C-peptide can move management from empirical glucose lowering toward pathophysiology-based treatment. The authors emphasize that standardized diagnostic criteria and prospective trials are still needed. 

🧠 CME INDIA PRACTICE MESSAGE

Adult “T2DM” + atypical phenotype / early treatment failure → Think LADA → Check GADA ± other islet antibodies + C-peptide → Reclassify → Individualize therapy → Do not delay insulin when β-cell reserve is failing.

One-line pearl:

> When an adult with presumed Type 2 diabetes behaves unlike Type 2 diabetes, question the diagnosis before adding another tablet.

link.springer.com/article/10.100…

https://x.com/CMEINDIA1/status/2098249312841109665